Buspirone is not a strong treatment for social anxiety disorder. It is FDA-approved for generalized anxiety disorder (GAD), and while some clinicians prescribe it off-label for social phobia, the controlled research behind that use is weak. In the most rigorous trial available, buspirone performed no better than a placebo for social anxiety symptoms.
What the Clinical Evidence Shows
The best direct evidence comes from a double-blind, placebo-controlled study that tested buspirone specifically in people with social phobia. Using a 50% reduction on a standard social phobia scale as the benchmark for meaningful improvement, only 1 patient on buspirone and 1 patient on placebo met that threshold. When patients were asked about subjective improvement, 27% of those on buspirone reported feeling better compared to 13% on placebo, but that difference was not statistically significant. The researchers found no meaningful separation between buspirone and placebo on any outcome measure.
Earlier open-label studies (where both patient and doctor knew what was being taken) had suggested buspirone might reduce social anxiety and avoidance. But those results didn’t hold up once a proper placebo comparison was added. This pattern is common in anxiety research: open studies often look promising because expectations alone can reduce anxiety symptoms.
Why It Works for GAD but Not Social Anxiety
Buspirone targets a specific type of serotonin receptor in the brain. This mechanism is effective at easing the chronic, free-floating worry that defines generalized anxiety disorder. In clinical trials for GAD, therapeutic effects typically appear at doses of 20 to 30 mg per day, and most people start to feel a decrease in irritability and worry after 3 to 4 weeks of consistent use.
Social anxiety disorder, however, involves a different constellation of symptoms. The fear response is triggered by specific social situations, often with intense physical reactions like blushing, sweating, or a racing heart. The brain circuits driving social threat perception don’t respond as reliably to buspirone’s mechanism of action. That’s why international treatment guidelines from organizations like the World Federation of Societies of Biological Psychiatry list SSRIs as first-line treatment for social phobia and don’t include buspirone even as a second-line option.
What Guidelines Recommend Instead
For social anxiety disorder, the established first-line medications are SSRIs such as paroxetine, sertraline, and escitalopram, along with the SNRI venlafaxine. These medications have large, well-controlled trials supporting their use specifically for social phobia. Second-line options in treatment guidelines include certain older antidepressants (MAOIs) and benzodiazepines.
Buspirone does appear as a recognized alternative for generalized anxiety disorder in these same guidelines, sitting alongside first-line options like venlafaxine and SSRIs. So if your anxiety is more of the constant, everyday worry variety rather than socially triggered fear, buspirone has a stronger evidence base. The distinction matters because GAD and social anxiety frequently overlap, and someone with both conditions might benefit from buspirone’s effect on general worry without seeing much change in their social anxiety specifically.
Buspirone as an Add-On to Antidepressants
One area where buspirone sometimes enters the picture is as an adjunctive therapy, meaning it’s added on top of an SSRI or SNRI that someone is already taking. A 2025 multicenter study in Korea found that adding buspirone to an existing antidepressant regimen improved anxiety symptoms in patients with depression, regardless of how severe their baseline anxiety was or what dose of buspirone they received. However, only about 4% of patients in that study had social anxiety disorder as a comorbidity, so the findings don’t speak directly to social phobia.
Buspirone is sometimes used this way because it can complement SSRIs without the sedation or dependence risk that comes with benzodiazepines. It can also help counteract certain SSRI side effects, particularly sexual dysfunction. But adding it specifically to target social anxiety that isn’t responding to an SSRI alone doesn’t have strong trial data behind it.
Side Effects Compared to SSRIs
One genuine advantage of buspirone is its side effect profile. The most common issues are dizziness, nausea, headache, and fatigue. It doesn’t cause the sexual dysfunction that SSRIs are notorious for, and it carries no risk of physical dependence or withdrawal symptoms. It also tends not to cause significant sedation or weight gain.
SSRIs and SNRIs, by comparison, can cause sedation, dizziness, nausea, sexual dysfunction, and falls (particularly in older adults). In head-to-head comparisons for GAD, buspirone users reported less dry mouth than those on venlafaxine, while venlafaxine users experienced less dizziness. Neither medication produced clinically serious adverse events in comparative trials.
This tolerability is likely why some clinicians still try buspirone for social anxiety despite the limited evidence. For someone who can’t tolerate SSRIs or who has concerns about specific side effects, it represents a low-risk option to attempt. But “low risk” and “effective” are different things, and the controlled data for social anxiety simply isn’t there.
What This Means If You’re Considering Buspirone
If you’re specifically struggling with social anxiety, fear of judgment in social situations, or avoidance of public speaking, meetings, or conversations, buspirone is unlikely to be the most effective medication choice. The best-studied options remain SSRIs and SNRIs, often combined with cognitive behavioral therapy, which has its own strong evidence base for social phobia.
If your anxiety is more generalized, with persistent worry across many areas of life that happens to include social situations, buspirone becomes more relevant. It takes 3 to 4 weeks to start working, doses typically land in the 20 to 30 mg per day range, and it can be increased gradually up to 60 mg per day. For that broader anxiety pattern, the evidence is solid. The key question is whether your primary problem is social anxiety specifically or general anxiety that shows up in social settings among other places.